Tenax Therapeutics, Inc. (TENX)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Tenax Therapeutics, Inc. (TENX) is up 0.5% since the beginning of the year. At $12 per share, TENX is trading 33.4% below its 52-week high of $18. Investors who bought $1,000 worth of TENX shares 5 years ago would now be looking at an investment worth $4.

Tenax Therapeutics, Inc. (TENX) has returned 0.49% so far this year and 111.57% over the past 12 months. Over the last ten years, TENX has returned -58.54% per year, falling short of the S&P 500 Index benchmark, which averaged 13.88% annually.

Based on dividend-adjusted daily data since Jan 2, 1997, TENX's average daily return is +0.11%, while the average monthly return is +1.33%. At this rate, an investment would double in approximately 4.4 years.

Historically, 38% of months were positive and 62% were negative. The best month was Feb 2000 with a return of +582.1%, while the worst month was Jan 2017 at -76.4%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 9 months.

On a daily basis, TENX closed higher 41% of trading days. The best single day was Nov 13, 2023 with a return of +297.4%, while the worst single day was Jan 31, 2017 at -76.4%.

Tenax Therapeutics, Inc. has an annualized alpha of 28.76%, beta of 0.36, and R2 of 0.00 versus S&P 500 Index. Calculated based on daily prices since January 02, 1997.

• This stock participated in 132.55% of S&P 500 Index downside but only -42.46% of its upside - more exposed to losses than it benefited from rallies.
• Beta of 0.36 may look defensive, but with R2 of 0.00 this stock is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
• R2 of 0.00 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

TENX ranks 82 for risk / return — in the top 82% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Tenax Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Tenax Therapeutics, Inc. was 100.00%, occurring on Jun 21, 2024. The portfolio has not yet recovered.

The current Tenax Therapeutics, Inc. drawdown is 100.00%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Tenax Therapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Tenax Therapeutics, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.